A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab

作者全名：Zhou, Yufan; Guo, Rongjing; Xia, Xingyu; Jing, Sisi; Lu, Jun; Ruan, Zhe; Luo, Sushan; Huan, Xiao; Zhao, Chongbo; Chang, Ting; Xi, Jianying

作者地址：[Zhou, Yufan; Xia, Xingyu; Lu, Jun; Luo, Sushan; Huan, Xiao; Zhao, Chongbo; Xi, Jianying] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai, Peoples R China; [Zhou, Yufan; Xia, Xingyu; Lu, Jun; Luo, Sushan; Huan, Xiao; Zhao, Chongbo; Xi, Jianying] Fudan Univ, Huashan Hosp, Huashan Rare Dis Ctr, Shanghai, Peoples R China; [Zhou, Yufan; Xia, Xingyu; Lu, Jun; Luo, Sushan; Huan, Xiao; Zhao, Chongbo; Xi, Jianying] Natl Ctr Neurol Dis, Shanghai, Peoples R China; [Guo, Rongjing; Ruan, Zhe; Chang, Ting] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian, Peoples R China; [Jing, Sisi] Chongqing Med Univ, Banan Hosp, Dept Neurol, Chongqing, Peoples R China

通信作者：Xi, JY (通讯作者)，Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai, Peoples R China.; Chang, T (通讯作者)，Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian, Peoples R China.

来源：CNS NEUROSCIENCE & THERAPEUTICS

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:001219619000001

JCR分区：Q1

影响因子：4.8

年份：2024

卷号：30

期号：5

开始页：　

结束页：　

文献类型：Article

关键词：myasthenia gravis; nomogram; predictor; prognosis; rituximab

摘要：BackgroundThis study aims to establish and validate a predictive nomogram for the short-term clinical outcomes of myasthenia gravis (MG) patients treated with low-dose rituximab.MethodsWe retrospectively reviewed 108 patients who received rituximab of 600 mg every 6 months in Huashan Hospital and Tangdu Hospital. Of them, 76 patients from Huashan Hospital were included in the derivation cohort to develop the predictive nomogram, which was externally validated using 32 patients from Tangdu Hospital. The clinical response is defined as a >= 3 points decrease in QMG score within 6 months. Both clinical and genetic characteristics were included to screen predictors via multivariate logistic regression. Discrimination and calibration were measured by the area under the receiver operating characteristic curve (AUC-ROC) and Hosmer-Lemeshow test, respectively.ResultsDisease duration (OR = 0.987, p = 0.032), positive anti-muscle-specific tyrosine kinase antibodies (OR = 19.8, p = 0.007), and genotypes in FCGR2A rs1801274 (AG: OR = 0.131, p = 0.024;GG:OR = 0.037, p = 0.010) were independently associated with clinical response of post-rituximab patients. The nomogram identified MG patients with clinical response with an AUC-ROC (95% CI) of 0.875 (0.798-0.952) in the derivation cohort and 0.741(0.501-0.982) in the validation cohort. Hosmer-Lemeshow test showed a good calibration (derivation: Chi-square = 3.181, p = 0.923; validation: Chi-square = 8.098, p = 0.424).ConclusionsThe nomogram achieved an optimal prediction of short-term outcomes in patients treated with low-dose rituximab. Our study developed and validated the clinical response prediction nomogram for myasthenia gravis patients treated with low-dose rituximab. The nomogram can effectively identify patients with clinical response, help make treatment-related decisions, alleviate the financial burden on patients, and rationalize the allocation of healthcare resources.image

基金机构：Shanghai Municipal Science and Technology Major Project

基金资助正文：The authors thank all the participants and their family members. The authors thank other authors who have contributed to the manuscript.